Let's talk about a controversial yet crucial topic in brain tumor management: the role of stereotactic radiosurgery in treating craniopharyngiomas. These tumors, though rare, pose unique challenges due to their location near critical brain structures. But here's where it gets controversial: while surgery is effective, it carries high risks. So, is there a better way?
Craniopharyngiomas, accounting for a small percentage of brain tumors, are tricky to manage due to their proximity to the hypothalamus, pituitary gland, and optic pathways. Gross total resection, though a common approach, often leads to visual, endocrine, and hypothalamic issues. This is where stereotactic radiosurgery (SRS) steps in as a potential game-changer.
SRS, unlike conventional radiotherapy, delivers highly targeted radiation with a rapid dose fall-off, making it ideal for tumors near sensitive structures. Platforms like Gamma Knife, CyberKnife, and LINAC-based systems offer different treatment options depending on tumor size and location. And this is the part most people miss: SRS minimizes radiation exposure to healthy tissues, reducing long-term risks like cognitive decline and secondary malignancies.
Meta-analyses show that SRS provides comparable long-term survival rates and endocrine outcomes to conventional radiotherapy, but with fewer complications. It's especially beneficial in preventing hypothalamic obesity and other long-term issues. Gamma Knife, the most studied SRS modality for craniopharyngiomas, achieves control rates up to 100% with marginal doses of 12 Gy or more. Smaller tumors and solid lesions respond better, and repeat SRS or combined approaches effectively manage recurrences.
CyberKnife and LINAC-based SRS offer flexibility for tumors near the optic apparatus or with cystic components. These platforms support fractionated treatment, adapting to cyst dynamics. Safety-wise, SRS has a favorable profile with low risks of visual and endocrine complications. Radiation necrosis and cognitive effects are rare, but higher maximum point doses may increase neurological risks over time.
Dose constraints are critical, especially for the optic chiasm and hypothalamus. In pediatric patients, stricter limits are essential to preserve long-term quality of life. Further research is needed to optimize dose and fractionation protocols, explore molecular targeting options, and conduct prospective multicenter trials with standardized outcome measures and longer follow-up periods.
In conclusion, stereotactic radiosurgery is a vital tool in the multidisciplinary management of craniopharyngiomas, particularly for residual or recurrent tumors. With ongoing technical advancements and a deeper understanding of molecular targets, SRS promises improved outcomes and a better quality of life for patients facing this challenging condition.
Source: Lin, Y., et al. (2025). Stereotactic Radiosurgery for Craniopharyngioma Management: A Comprehensive Review. Neurosurgical Subspecialties. doi: doi.org/10.14218/nsss.2025.00038.
